Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026

Topics will include:

• Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the planned confirmatory Phase 3 trial
• Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across AP3-prioritized solid tumor types
• Nomination of new preclinical development candidate, including target disclosure, for Acrivon's AP3-driven cell cycle program